retinal vein occlusion epidemiology forecast insight
DelveInsight’s ‘Retinal Vein Occlusion—Epidemiology Forecast–2034’ report delivers an in-depth understanding of the disease, historical and forecasted Retinal Vein Occlusion epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2021-2034
Retinal Vein Occlusion Understanding
Retinal vein occlusion, one of the most frequently occurring retinal vascular disorders in elderly patients, develops predominantly in individuals over age 65 years. The main risk factors for Retinal Vein Occlusion include age and systemic vascular disorders. It is categorized into central Retinal Vein Occlusion (CRetinal Vein Occlusion) and branch Retinal Vein Occlusion (BRetinal Vein Occlusion) according to the site of blockage in the retinal vein. CRetinal Vein Occlusion is divided further into nonischemic and ischemic types according to the perfusion status based on fluorescein angiography. BRetinal Vein Occlusion consists of major branch Retinal Vein Occlusion (when one of the major branch retinal veins is occluded, usually near, or rarely at, the optic disc) and macular branch Retinal Vein Occlusion (when only one of the macular venules is occluded). Macular edema is the major complication of significant visual loss in patients with CRetinal Vein Occlusion and BRetinal Vein Occlusion, and various treatments have been used to improve macular edema and cause regression of intraocular neovascularization.
The initial examination of a patient with an Retinal Vein Occlusion includes all relevant aspects of the comprehensive adult medical eye evaluation, with particular attention to those aspects related to retinal vascular disease. Several tests are being used for the diagnosis of Retinal Vein Occlusion such as Optical coherence tomography (OCT), and fluorescein angiography (FA). Apart from this, Systemic evaluation is often performed in patients with CRetinal Vein Occlusion and is directed by the patient’s age, coexisting risk factors, and medical history. In Retinal Vein Occlusion, intravitreal steroids and anti-VEGF therapy are used in cases of macular perfusion and macular ischemia, with the laser of use in situations of neovascularization. Response to treatment may be measured by improvement of visual acuity (as a measure of photoreceptor status) and retinal thickness (as a measure of leakage).
Retinal Vein Occlusion Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Retinal Vein Occlusion, Diagnosed Prevalent Cases of Retinal Vein Occlusion, Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion, Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion, Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion, and Treated Cases of Retinal Vein Occlusion in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2021 to 2034.
Retinal Vein Occlusion Detailed Epidemiology Segmentation
- In the year 2020, the total prevalent cases of Retinal Vein Occlusion were 2,308,457 cases in the 7MM, which is expected to increase in the forecast period (2025-2034).
- The United States, in 2020, accounted for 1,160,900 cases prevalent cases of Retinal Vein Occlusion, which is expected to rise in the year 2034. In EU-5 countries the highest number of prevalent Cases of Retinal Vein Occlusion was in Germany, i.e., 217,282, in the year 2020. The lowest number of cases observed in Spain during the study period.
- In 2020, the total diagnosed prevalent cases of Retinal Vein Occlusion in the 7MM were 2,020,233.
- In the 7MM, the total gender-specific prevalent cases of Retinal Vein Occlusion were 951,432 in males and 1,068,801 in females in the year 2020
- In the 7MM, the total diagnosed cases of Retinal Vein Occlusion by age distribution were 1,166,736, 535,472, and 318,025 cases for the age group less than 65 years, 65-74 years, and ≥75 years, in 2020.
- In the 7MM, CRetinal Vein Occlusion contributed to 407,058 cases in 2020. Furthermore, in 2020, there were around 1,613,175 BRetinal Vein Occlusion cases.
Scope of the Report
- The report covers the descriptive overview of Retinal Vein Occlusion, explaining its causes, signs, and symptoms, and pathophysiology.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.
- The report assesses the disease risk and burden.
- The report provides the segmentation of the disease epidemiology for 7MM by Prevalent Cases, Diagnosed Prevalent Cases, Gender-Specific Diagnosed Prevalent Cases, Age-Specific Diagnosed Prevalent Cases, Type-Specific Diagnosed Prevalent Cases, and Treated Cases.
Report Highlights
- 10-Year Forecast of Retinal Vein Occlusion
- 7MM Coverage of Retinal Vein Occlusion
- Prevalent Cases of Retinal Vein Occlusion in the 7MM
- Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM
- Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM
- Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM
- Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM
- Treated Cases of Retinal Vein Occlusion in the 7MM
Key Questions Answered
- What are the disease risk, burdens, and unmet needs of Retinal Vein Occlusion?
- What is the historical Retinal Vein Occlusion patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Retinal Vein Occlusion at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Retinal Vein Occlusion?
- Out of the countries mentioned above, which country would have the highest prevalent population of Retinal Vein Occlusion during the forecast period (2025-2034)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2025-2034)?
Reasons to buy
The Retinal Vein Occlusion report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM Retinal Vein Occlusion market.
- Quantify patient populations in the 7MM Retinal Vein Occlusion market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the specific type of Retinal Vein Occlusion that presents the best opportunities for Retinal Vein Occlusion therapeutics in each of the markets covered.
- The Retinal Vein Occlusion epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The Retinal Vein Occlusion epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
1. Key Insights
2. Executive Summary of Retinal Vein Occlusion
3. Retinal Vein Occlusion: Disease Background and Overview
3.1. Introduction
3.2. Signs and Symptoms
3.3. Risk Factors and Causes
3.4. Pathophysiology
3.5. Diagnosis
3.5.1. Optical coherence tomography
3.5.2. Fluorescein angiography
3.5.3. Systemic Evaluation
3.5.4. Optical coherence tomography angiography (OCTA)
3.5.5. Fundus Autofluorescence
3.5.6. Laboratory Test
3.5.7. European Society of Retina Specialists Diagnostic Guidelines
4. Epidemiology and Patient Population
4.1. Epidemiology Key Findings
4.2. Assumptions and Rationale
4.3. Epidemiology Scenario: 7MM
4.3.1. Total Prevalent Cases of Retinal Vein Occlusion in the 7MM
4.3.2. Total Diagnosed Prevalent cases of Retinal Vein Occlusion in the 7MM
4.3.3. Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM
4.3.4. Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM
4.3.5. Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM
4.3.6. Treated cases of Retinal Vein Occlusion in the 7MM
4.4. The United States Epidemiology
4.4.1. Total Prevalent Cases of Retinal Vein Occlusion in the United States
4.4.2. Total Diagnosed Prevalent cases of Retinal Vein Occlusion in the United States
4.4.3. Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United States
4.4.4. Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United States
4.4.5. Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United States
4.4.6. Treated cases of Retinal Vein Occlusion in the United States
4.5. EU-5 Epidemiology
4.6. Germany
4.6.1. Total Prevalent Cases of Retinal Vein Occlusion in Germany
4.6.2. Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Germany
4.6.3. Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Germany
4.6.4. Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Germany
4.6.5. Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Germany
4.6.6. Treated cases of Retinal Vein Occlusion in Germany
4.7. France
4.7.1. Total Prevalent Cases of Retinal Vein Occlusion in France
4.7.2. Total Diagnosed Prevalent cases of Retinal Vein Occlusion in France
4.7.3. Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in France
4.7.4. Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in France
4.7.5. Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in France
4.7.6. Treated cases of Retinal Vein Occlusion in France
4.8. Italy
4.8.1. Total Prevalent Cases of Retinal Vein Occlusion in Italy
4.8.2. Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Italy
4.8.3. Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Italy
4.8.4. Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Italy
4.8.5. Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Italy
4.8.6. Treated cases of Retinal Vein Occlusion in Italy
4.9. Spain
4.9.1. Total Prevalent Cases of Retinal Vein Occlusion in Spain
4.9.2. Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Spain
4.9.3. Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Spain
4.9.4. Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Spain
4.9.5. Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Spain
4.9.6. Treated cases of Retinal Vein Occlusion in Spain
4.10. The United Kingdom
4.10.1. Total Prevalent Cases of Retinal Vein Occlusion in the United Kingdom
4.10.2. Total Diagnosed Prevalent cases of Retinal Vein Occlusion in the United Kingdom
4.10.3. Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United Kingdom
4.10.4. Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United Kingdom
4.10.5. Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United Kingdom
4.10.6. Treated cases of Retinal Vein Occlusion in the United Kingdom
4.11. Japan Epidemiology
4.11.1. Total Prevalent Cases of Retinal Vein Occlusion in Japan
4.11.2. Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Japan
4.11.3. Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Japan
4.11.4. Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Japan
4.11.5. Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Japan
4.11.6. Treated cases of Retinal Vein Occlusion in Japan
5. Recognized Establishments
6. Appendix
6.1. Bibliography
6.2. Report Methodology
7. DelveInsight Capabilities
8. Disclaimer
9. About DelveInsight
List of Tables:
List of Table
Table 1: Summary of Retinal Vein Occlusion, Epidemiology, and Key Events (2021-2034)
Table 2: Total Prevalent Cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Table 3: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Table 4: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Table 5: Age-specific Prevalent Cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Table 6: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Table 7: Total Treated cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Table 8: Total Prevalent Cases of Retinal Vein Occlusion in the United States (2021-2034)
Table 9: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in the United States (2021-2034)
Table 10: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United States (2021-2034)
Table 11: Age-specific Prevalent Cases of Retinal Vein Occlusion in the United States (2021-2034)
Table 12: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United States (2021-2034)
Table 13: Total Treated cases of Retinal Vein Occlusion in the US (2021-2034)
Table 14: Total Prevalent Cases of Retinal Vein Occlusion in Germany (2021-2034)
Table 15: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Germany (2021-2034)
Table 16: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Germany (2021-2034)
Table 17: Age-specific Prevalent Cases of Retinal Vein Occlusion in Germany (2021-2034)
Table 18: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Germany (2021-2034)
Table 19: Total Treated cases of Retinal Vein Occlusion in Germany (2021-2034)
Table 20: Total Prevalent Cases of Retinal Vein Occlusion in France (2021-2034)
Table 21: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in France (2021-2034)
Table 22: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in France (2021-2034)
Table 23: Age-specific Prevalent Cases of Retinal Vein Occlusion in France (2021-2034)
Table 24: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in France (2021-2034)
Table 25: Total Treated cases of Retinal Vein Occlusion in France (2021-2034)
Table 26: Total Prevalent Cases of Retinal Vein Occlusion in Italy (2021-2034)
Table 27: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Italy (2021-2034)
Table 28: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Italy (2021-2034)
Table 29: Age-specific Prevalent Cases of Retinal Vein Occlusion in Italy (2021-2034)
Table 30: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Italy (2021-2034)
Table 31: Total Treated cases of Retinal Vein Occlusion in Italy (2021-2034)
Table 32: Total Prevalent Cases of Retinal Vein Occlusion in Spain (2021-2034)
Table 33: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Spain (2021-2034)
Table 34: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Spain (2021-2034)
Table 35: Age-specific Prevalent Cases of Retinal Vein Occlusion in Spain (2021-2034)
Table 36: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Spain (2021-2034)
Table 37: Total Treated cases of Retinal Vein Occlusion in Spain (2021-2034)
Table 38: Total Prevalent Cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Table 39: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Table 40: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Table 41: Age-specific Prevalent Cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Table 42: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Table 43: Total Treated cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Table 44: Total Prevalent Cases of Retinal Vein Occlusion in Japan (2021-2034)
Table 45: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Japan (2021-2034)
Table 46: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Japan (2021-2034)
Table 47: Age-specific Prevalent Cases of Retinal Vein Occlusion in Japan (2021-2034)
Table 48: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Japan (2021-2034)
Table 49: Total Treated cases of Retinal Vein Occlusion in Japan (2021-2034)
Table 50: Decisions for visual impairment due to macular edema secondary to retinal vein occlusion (branch BRetinal Vein Occlusion or central CRetinal Vein Occlusion) by different HTA agencies in Europe
List of Figures:
List of Figures
Figure 1: Changes in the eye
Figure 2: Retinal Vein Occlusion with hemorrhage
Figure 3: Branch Retinal Vein Occlusion
Figure 4: Signs and symptoms
Figure 5: Risk factors of Retinal Vein Occlusion
Figure 6: Pathophysiology of Retinal Vein Occlusion
Figure 7: Optical coherence tomography
Figure 8: Fluorescein angiography
Figure 9: Fundus autofluorescence
Figure 10: Total Prevalent Cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Figure 11: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Figure 12: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Figure 13: Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Figure 14: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Figure 15: Treated cases of Retinal Vein Occlusion in the 7MM (2021-2034)
Figure 16: Total Prevalent Cases of Retinal Vein Occlusion in the United States (2021-2034)
Figure 17: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in the United States (2021-2034)
Figure 18: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United States (2021-2034)
Figure 19: Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United States (2021-2034)
Figure 20: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United States (2021-2034)
Figure 21: Treated cases of Retinal Vein Occlusion in the United States (2021-2034)
Figure 22: Total Prevalent Cases of Retinal Vein Occlusion in Germany (2021-2034)
Figure 23: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Germany (2021-2034)
Figure 24: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Germany (2021-2034)
Figure 25: Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Germany (2021-2034)
Figure 26: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Germany (2021-2034)
Figure 27: Treated cases of Retinal Vein Occlusion in Germany (2021-2034)
Figure 28: Total Prevalent Cases of Retinal Vein Occlusion in France (2021-2034)
Figure 29: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in France (2021-2034)
Figure 30: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in France (2021-2034)
Figure 31: Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in France (2021-2034)
Figure 32: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in France (2021-2034)
Figure 33: Treated cases of Retinal Vein Occlusion in France (2021-2034)
Figure 34: Total Prevalent Cases of Retinal Vein Occlusion in Italy (2021-2034)
Figure 35: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Italy (2021-2034)
Figure 36: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Italy (2021-2034)
Figure 37: Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Italy (2021-2034)
Figure 38: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Italy (2021-2034)
Figure 39: Treated cases of Retinal Vein Occlusion in Italy (2021-2034)
Figure 40: Total Prevalent Cases of Retinal Vein Occlusion in Spain (2021-2034)
Figure 41: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Spain (2021-2034)
Figure 42: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Spain (2021-2034)
Figure 43: Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Spain (2021-2034)
Figure 44: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Spain (2021-2034)
Figure 45: Treated cases of Retinal Vein Occlusion in Spain (2021-2034)
Figure 46: Total Prevalent Cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Figure 47: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Figure 48: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Figure 49: Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Figure 50: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Figure 51: Treated cases of Retinal Vein Occlusion in the United Kingdom (2021-2034)
Figure 52: Total Prevalent Cases of Retinal Vein Occlusion in Japan (2021-2034)
Figure 53: Total Diagnosed Prevalent cases of Retinal Vein Occlusion in Japan (2021-2034)
Figure 54: Gender-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Japan (2021-2034)
Figure 55: Age-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Japan (2021-2034)
Figure 56: Type-specific Diagnosed Prevalent Cases of Retinal Vein Occlusion in Japan (2021-2034)
Figure 57: Treated cases of Retinal Vein Occlusion in Japan (2021-2034)
